Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
23 hedge funds and large institutions have $471K invested in Oncternal Therapeutics, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 6 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
12% less funds holding
Funds holding: 26 → 23 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
87% less capital invested
Capital invested by funds: $3.67M → $471K (-$3.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$59.3K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$10.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$5.41K |
| 4 |
Renaissance Technologies
New York
|
+$3.38K |
| 5 |
BlackRock
New York
|
+$2.07K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$202K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$200K |
| 3 |
RB
Richmond Brothers
Jackson,
Michigan
|
-$188K |
| 4 |
BJL
Brighton Jones LLC
Seattle,
Washington
|
-$129K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$116K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BJL
26
Brighton Jones LLC
Seattle,
Washington
| – | -$129K | -16,923 | Closed |
|
|
27
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$116K | -15,206 | Closed |
|
28
US Bancorp
Minneapolis,
Minnesota
| – | -$760 | -100 | Closed |
|
29
Fidelity Investments
Boston,
Massachusetts
| – | -$547 | -72 | Closed |
|
ONCT Hedge Fund Activity: Q3 2024 in Review
23 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q3 2024, worth a combined $471K — down 87% from $3.67M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ONCT and 3 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 6 added.
The largest buyer was Virtu Financial, opening a new position worth an estimated $59.3K. The largest seller was Millennium Management, cutting an estimated $202K.
- 23 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q3 2024, down from 26 in Q2 2024.
- Funds reported $471K of Oncternal Therapeutics, Inc. Common Stock stock for Q3 2024, down 87% quarter-over-quarter.
- 3 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q3 2024 and 6 closed out, a net change of -3 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q3 2024 was Virtu Financial, an estimated $59.3K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q3 2024 was Millennium Management, an estimated $202K sold.
Based on aggregated 13F filings for Q3 2024.